All treatments
Treatment
Casodex® 50 mg Film-coated Tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD
This study is looking at how a new treatment for prostate cancer, called enzalutamide, works when used with standard hormone therapy and radiation. It's for men with prostate cancer that hasn't spread but is considered high-risk. We want to see if this combination stops the cancer from spreading.
For: Localised prostate cancer at high risk of recurrenceAustria · Ireland · Spain - AuthorisedTherapeutic confirmatory (Phase III)
One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.
This study is looking at a new treatment called SHR3680 for men with prostate cancer that has spread. It compares SHR3680 plus standard hormone therapy against another common treatment, Bicalutamide, plus standard hormone therapy, to see which works better and is safer.
For: Metastatic hormone-sensitive prostate cancer with high tumor loadCzechia · Bulgaria · Poland